Definitive Contract 75F40125C00053
Award Date
9/8/25
Potential Completion Date
3/31/28
Potential Value
$750K
Federal Agency
Food and Drug Administration
Awardee
Duke University
Ultimate Awardee
Not listed
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27705, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $696,359 firm-fixed-price contract to Duke University's Office of Research Administration Division to conduct research and development activities in support of regulatory science and innovation. The contract, which does not have a set-aside designation, originated from a Broad Agency Announcement (BAA) that solicits advanced proposals across nine key areas to advance scientific knowledge in support of the FDA's mission to protect public...
The U.S. Food and Drug Administration (FDA) has awarded a $1,567,108.00 definitive cost-no-fee contract to Duke University to conduct a study on Medicare Advantage for real-world evidence in cardiovascular disease. The contract has an ultimate completion date of September 29, 2026. Duke University, a prominent private research university, will be the prime contractor for this effort, which is not set aside under any special program. The contract award indicates Duke University's extensive...
Duke University has been awarded a firm fixed price purchase order totaling $22,137 by the Department of Health and Human Services Food and Drug Administration. The contract is for technical expertise in predictive toxicology for drug-induced liver injury to be delivered through April 2025 in Durham, North Carolina. As the prime contractor, Duke University will provide technical expert services through its Office of Research Administration to support the FDA's predictive toxicology programs....
Duke University Office of Research Administration Division was awarded a $274,413 definitive contract by the Department of Health and Human Services Food and Drug Administration to conduct a study using electronic health records to identify and assess adverse events for biologic therapies. The contract aims to develop and validate methodological approaches under the agency's Broad Agency Announcement for the Advanced Research and Development of Regulatory Science, which seeks proposals to...
This federal contract was awarded to Duke University by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to support the development and deployment of COVID-19 vaccines under Operation Warp Speed. The $281,376.08 definitive cost-no-fee contract, awarded on September 17, 2021, does not have a set-aside designation. The contract supports research and development activities to advance regulatory science and innovation, which aligns with Duke University's expertise...
This is a $1,206,589.24 firm fixed-price contract awarded by the Food and Drug Administration (FDA) to Duke University's Office of Research Administration Division. The contract is for research and development to quantify patient priorities for clinical evidence on the impact of osseointegrated limb prostheses. This award was made under the FDA's Broad Agency Announcement for regulatory science and innovation research, with no set-aside designation. Duke University has previously received...
This federal contract award was made by the Naval Sea Systems Command (NAVSEA), a defense agency, to Duke University, a private research university. The contract, valued at $1,991,019.00, is for a research study with a final completion date of February 13, 2030. The contract type is a definitive contract with a cost-no-fee pricing structure. Duke University has also been awarded a significant single-award Indefinite Delivery Vehicle (IDV) with the National Institute of Allergy and Infectious...
This is a $494,060 Definitive Contract awarded by the Food and Drug Administration (FDA) to Drexel University, a private research university located in Philadelphia. The contract was awarded under the FDA's Broad Agency Announcement (BAA) seeking research and development proposals to advance regulatory science. Specifically, the contract is for the development of "machine-learning based heterogeneous treatment effect models for prioritizing product-specific guidance development."...
This federal contract award, valued at $400,734.35, was made by the Defense Health Agency to Duke University, a private non-profit university, for a new research contract. The award does not have a set-aside designation. The contract is a definitive contract of the cost-no-fee pricing type, with a performance period ending on December 29, 2018. Duke University's Office of Research Administration Division is the prime contractor. The award indicates that Duke University has been awarded...
Duke University is the prime contractor on a $1,609,333 cost-no-fee definitive contract with the Department of Health and Human Services' Food and Drug Administration to perform research titled "Quantifying Patients' Benefit-Risk Tradeoffs Associated with Percutaneous Revascularization Options for Peripheral Arterial Disease: A Collaborative Effort with the Rapid Pathways Patient Science Working Group." There is no set-aside designation. Major subcontractors include the University of...